Aclaris Therapeutics (ACRS) Return on Sales (2017 - 2026)

Aclaris Therapeutics' Return on Sales history runs 10 years deep, the most recent figure standing at 0.19% for Q1 2026.

• On a quarterly basis, Return on Sales fell 6.0% year-over-year to 0.19% in Q1 2026; TTM through Mar 2026 was 0.13%, a 4.0% decrease from a year earlier, with the FY2025 full-year figure at 0.35%, down 28.0% from the prior year.
• Return on Sales climbed to 0.19% in Q1 2026 per ACRS's latest filing, from 0.24% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q4 2023 and bottomed at 0.27% in Q4 2022.
• The 5-year median for Return on Sales is 0.12% (2024), against an average of 0.12%.
• Across the five-year window, Return on Sales soared 96 bps in 2022 and declined 12 bps in 2024, its largest moves.
• Year by year, Return on Sales stood at 0.27% in 2022, then jumped by 100 bps to 0.0% in 2023, then plunged by 10934 bps to 0.12% in 2024, then sank by 106 bps to 0.24% in 2025, then grew by 22 bps to 0.19% in 2026.
• Per Business Quant, the three latest ACRS Return on Sales figures stand at 0.19% (Q1 2026), 0.24% (Q4 2025), and 0.06% (Q3 2025).